Treatment of alopecia areata partim universalis with efalizumab - 09/08/11
Reprint requests: N. Yawalkar, MD, Department of Dermatology, University of Bern Inselspital, 3010 Bern, Switzerland.Bern, Switzerland
Abstract |
Alopecia areata (AA) is considered an autoimmune disease targeted at hair follicles with T-lymphocytes playing an important role in the pathogenesis. Treatment of AA, particularly the totalis and universalis subtypes, is often difficult and remains a therapeutic challenge. Novel biologic therapies that have been developed for the treatment of other immune-mediated inflammatory skin diseases may represent a new therapeutic modality for this disease. Efalizumab is a humanized monoclonal anti-CD11a antibody that inhibits T-cell activation and migration. We report a case of a 19-year-old man suffering from AA partim universalis, treated with efalizumab monotherapy. The treatment was well tolerated with no reported side effects. The striking improvement warrants further studies with this biologic therapy in AA.
Le texte complet de cet article est disponible en PDF.Plan
| Funding sources: Serono Pharma Switzerland provided efalizumab. Conflicts of interest: Dr Braathen has served as a consultant to Biogen, Essex, Wyeth Pharmaceuticals, and Serono. Dr Yawalkar has served as a consultant to Biogen, Wyeth Pharmaceuticals, and Serono. Dr Yawalkar has received research trial support from Biogen and Serono. |
Vol 55 - N° 3
P. 529-532 - septembre 2006 Retour au numéro
Article précédent
- Acute generalized exanthematous pustulosis following a spider bite: Report of 3 cases
- Batya B. Davidovici, Dyachenko Pavel, Emanuela Cagnano, Dganit Rozenman, Sima Halevy, for the EuroSCAR and RegiSCAR study group
- Intravenous cidofovir-induced resolution of disfiguring cutaneous human papillomavirus infection
- Margaret D. Kottke, Sareeta R.S. Parker
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?